BRIEFCASE | SEARCH | EMAIL THIS EVENT | LOGIN    
RSNA 2003 Scientific Papers > Hot Topic: Heat-Sensitive Liposomes as Carriers for ...
 
  Scientific Papers
  SESSION: Vascular Interventional (Interventions)

Hot Topic: Heat-Sensitive Liposomes as Carriers for Doxorubicin Increase Local Drug Deposition during Radiofrequency Ablation

  DATE: Tuesday, December 02 2003
  START TIME: 03:50 PM
  END TIME: 03:57 PM
  LOCATION: Room E451B
  CODE: J10-0
TOOLS
 
ADD TO BRIEFCASE
  PRINT
  EMAIL

PARTICIPANTS
PRESENTER
William Pritchard MD, PhD
Rockville , MD
 
CO-AUTHOR
Marc Friedman
 
Diane Wray-Cahen PhD
 
John Karanian PhD
 
Mark Dewhirst DVM, PhD
 
Bradford Wood MD
 
et al
 

Special
Hot Topics
 
Abstract:

Abstract #800056

Purpose: Compare deposition of doxorubicin in the periphery of thermal lesions in swine liver using free doxorubicin or a heat-sensitive liposomal vector containing doxorubicin as an adjuvant therapy to radiofrequency ablation (FRA).

Materials and Methods: Three pigs underwent RFA of the liver during intravenous administration of a low-temperature sensitive formulation of liposomal doxorubicin that deploys its contents at predominantly 39 to 42C. Two pigs were treated with identical RFA with intravenous free doxorubicin without liposome. Doxorubucin dosing was 0.7mg/kg body weight. Two pigs underwent ablation without drug, serving as controls. Liver tissue specimens collected at regular intervals from the thermal ablation center were analyzed for doxorubicin and its metabolites (aglycone and doxorubicinol)). Thermal maps and corresponding drug levels were analyzed and the area under the time temperature curve for specific distances was correlated.

Results: Between 2 to 4 times as much doxorubicin was deposited in and around the thermal lesions with the low temperature sensitive formulation of liposomal doxorubicin compared with free doxorubicin.

Conclusion: Liposome-encapsulated doxorubicin (with special low temperature deployment chemistry) may be deposited at the periphery of thermal lesions in the swine model. This combination treatment may prove more effective as a therapy for focal liver tumor than either treatment alone.  (M.A. is a paid consultant for Celsion, Inc; Celsion Inc. provided the liposomal carrier.)